Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market By Infection Type (Cellulitis/Erysipelas, Major Cutaneous Abscesses, Wound Infections); By Drug Class (Cephalosporins, Glycopeptides, Lipoglycopeptides, Oxazolidinones, Lipopeptides, Tetracyclines, Other Antibiotics); By Route of Administration (Intravenous (IV), Oral); By Pathogen Type (Methicillin-Resistant Staphylococcus aureus (MRSA), Methicillin-Susceptible Staphylococcus aureus (MSSA), Streptococcus Species, Other Bacterial Pathogens); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

How Are Antibiotic Resistance and Advanced Antimicrobial Therapies Reshaping the Acute Bacterial Skin and Skin Structure Infections Market? – (Updated On: 15th-Oct-2026)

The Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market was valued at USD 3.71 billion in 2025 and is projected to reach USD 5.77 billion by 2032, expanding at a CAGR of 6.52% during 2026–2032, according to Strategic Market Research. The market encompasses antibiotics used to treat serious bacterial infections affecting the skin and underlying soft tissues, particularly cellulitis/erysipelas, major cutaneous abscesses, and wound infections.

 

In the United States, a clinical study presented in 2025 evaluated 536 patients with culture-negative ABSSSI, documenting treatment failure in 31.3% of doxycycline-treated patients, 16.8% of cephalexin-treated patients, and 18.5% of trimethoprim-sulfamethoxazole-treated patients. These findings highlight the importance of appropriate antibiotic selection and effective oral treatment regimens. The FDA-approved antibiotic ceftobiprole (Zevtera) is supported by an ABSSSI clinical trial involving 679 patients, with 91.3% achieving an early clinical response in the ceftobiprole treatment group. Its U.S. approval in April 2024 expanded available intravenous treatment options for adult ABSSSI patients

 

Internationally, a pediatric ABSSSI study published in 2025 evaluated 100 patients across 20 clinical centers in 14 countries, including 54 patients with cutaneous abscesses, 25 with cellulitis, and 20 with wound infections. A total of 84 patients required inpatient care at enrollment, representing 84% of the study population, while clinical treatment success exceeded 90% in the evaluated treatment groups. The findings demonstrate the clinical importance of intravenous and oral antibiotic options for pediatric bacterial skin infections.

 

Commercial competition reflects developments in targeted antimicrobial technologies. Merck's SIVEXTRO (tedizolid phosphate) provides a six-day oral or intravenous oxazolidinone treatment regimen, supported by two Phase III studies involving 1,333 patients. Pfizer's ZYVOX (linezolid) offers oral and intravenous treatment for susceptible Gram-positive skin infections, while AbbVie's DALVANCE (dalbavancin) provides a single-dose intravenous lipoglycopeptide option

 

Overall, the Acute Bacterial Skin and Skin Structure Infections Market is progressing toward targeted antibiotic selection, MRSA-active therapies, simplified dosing schedules, and outpatient infection management. Commercial opportunities are concentrated in oral antibiotics, advanced intravenous formulations, long-acting lipoglycopeptides, hospital antibiotic procurement, and treatments offering effective clinical outcomes with manageable safety profiles. These developments support investment in differentiated ABSSSI therapies that improve treatment convenience, support antibiotic stewardship, and facilitate appropriate outpatient care.

 

Which Subsegments Are Leading Revenue Generation and Accelerating Growth in the Acute Bacterial Skin and Skin Structure Infections Market?

By Infection Type: Cellulitis Leads While Major Cutaneous Abscess Treatments Expand Faster

Leading Subsegment – Cellulitis/Erysipelas

Cellulitis and erysipelas represent the leading infection category within the Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) Market, accounting for approximately 52% of the global market, equivalent to USD 1.929 billion in 2025, with a projected CAGR of 6.39% during 2026–2032. Both infections involve bacterial invasion of the skin and underlying tissues, predominantly associated with Streptococcus and Staphylococcus species. Their substantial clinical burden, recurring infections, and frequent requirements for oral or intravenous antibiotic treatment reinforce their importance in ABSSSI therapeutics.

Fastest-Growing Subsegment – Major Cutaneous Abscesses

Major Cutaneous Abscesses accounted for 29% of the global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, representing approximately USD 1.076 billion in 2025, and are projected to register the fastest CAGR of 7.24% during 2026–2032. The FDA defines major cutaneous abscesses as purulent skin infections involving a minimum lesion surface area of 75 cm², representing one of four principal ABSSSI categories alongside cellulitis, erysipelas, and major wound infections. Treatment primarily involves incision and drainage, supported by systemic antibiotics when clinically indicated.

 

By Drug Class: Cephalosporins Lead While Long-Acting Lipoglycopeptides Expand Faster

Leading Subsegment – Cephalosporins

Cephalosporins hold the largest drug-class share in the Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, accounting for 23% and an estimated USD 0.853 billion in 2025, with a projected CAGR of 5.76% during 2026–2032. Their established clinical role includes first-line and alternative empirical treatment of bacterial skin infections, depending on antibiotic generation, pathogen susceptibility, and infection severity. Agents such as cefazolin, cephalexin, and ceftaroline support treatment across selected uncomplicated and severe infections, including cases requiring hospitalization and intravenous antibiotic therapy.

Fastest-Growing Subsegment – Lipoglycopeptides

Lipoglycopeptides, a class of semisynthetic antibacterial agents comprising dalbavancin, oritavancin, and telavancin, are used to treat acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Within the Acute Bacterial Skin and Skin Structure Infections Market, lipoglycopeptides accounted for an estimated 14% market share, valued at USD 0.519 billion in 2025, and are projected to register the fastest CAGR of 9.16% during 2026–2032, supported by long-acting formulations, simplified dosing schedules, and outpatient treatment opportunities.

 

By Route of Administration: Intravenous Treatment Leads While Oral Step-Down Therapy Expands

Leading Subsegment – Intravenous Administration

Intravenous (IV) administration accounted for the largest share of the Acute Bacterial Skin and Skin Structure Infections Market, representing 57% of the global market, valued at approximately USD 2.115 billion in 2025, with a projected CAGR of 6.08% during 2026–2032. IV antibiotics remain essential for managing severe, deep, and drug-resistant ABSSSIs, including extensive cellulitis, complicated abscesses, and infections requiring hospitalization. Their clinical importance is reinforced by rapid systemic drug delivery, reliable antibiotic exposure, and treatment of patients requiring intensive infection management.

Fastest-Growing Subsegment – Oral Administration

Oral administration plays a central role in treating mild-to-moderate Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) and supports step-down therapy following initial intravenous treatment in clinically stabilized patients. Oral administration accounted for 43% of the global Acute Bacterial Skin and Skin Structure Infections Market, valued at USD 1.595 billion in 2025, and is projected to expand at a CAGR of 7.08% during 2026–2032. Its clinical importance reflects outpatient treatment accessibility, reduced hospitalization requirements, and the availability of effective oral antibiotics for eligible patients.

 

By Pathogen Type: MRSA Leads Treatment Expenditure and Growth

Leading and Fastest-Growing Subsegment – Methicillin-Resistant Staphylococcus aureus (MRSA)

Methicillin-resistant Staphylococcus aureus (MRSA) is a leading bacterial pathogen associated with acute bacterial skin and skin structure infections (ABSSSIs), particularly purulent abscesses, cellulitis, and complicated wound infections. MRSA accounted for the largest pathogen-based share of the Acute Bacterial Skin and Skin Structure Infections Market at 35%, equivalent to USD 1.298 billion in 2025, and is projected to register the fastest CAGR of 7.59% during 2026–2032. Its clinical significance supports the continued use of MRSA-active antibiotics, including vancomycin, linezolid, and daptomycin.

 

By Distribution Channel: Hospital Pharmacies Lead While Online Prescription Access Expands

Leading Subsegment – Hospital Pharmacies

Hospital Pharmacies accounted for the largest distribution share in the Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, representing 61% of the global market, valued at approximately USD 2.263 billion in 2025, with a projected CAGR of 6.07% during 2026–2032. Hospital pharmacies and clinical pharmacists play a critical role in managing severe cellulitis, major cutaneous abscesses, and infected wounds through antimicrobial stewardship programs, intravenous antibiotic administration, appropriate antibiotic selection, dosage optimization, and monitoring of treatment outcomes in hospitalized patients.

Fastest-Growing Subsegment – Online Pharmacies

Online pharmacies accounted for 6% of the Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, valued at approximately USD 0.223 billion in 2025, and are projected to register the fastest CAGR of 8.37% during 2026–2032. Their growing role involves facilitating prescription-based access to oral antibiotics prescribed for cellulitis, major cutaneous abscesses, and infected wounds, particularly during outpatient treatment and post-discharge care. Digital prescription services and home delivery support treatment continuity, although severe infections generally require hospital-based intravenous antibiotic therapy and clinical supervision.

 

By Geography: North America Leads Advanced Antibiotic Access While Asia-Pacific Accelerates Growth

Leading Region – North America

North America leads the Acute Bacterial Skin and Skin Structure Infections Market, accounting for a 39% global share, valued at approximately USD 1.447 billion in 2025, with a projected CAGR of 5.88% during 2026–2032. The region benefits from established hospital infection management practices and access to FDA-approved antibiotics. The U.S. Food and Drug Administration formally introduced the ABSSSI classification, encompassing cellulitis, major cutaneous abscesses, and wound infections, to standardize clinical evaluation and support antibiotic development for serious bacterial skin infections.

Fastest-Growing Region – Asia-Pacific

Asia-Pacific region accounts for 25% of the global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, valued at approximately USD 0.927 billion in 2025, and is projected to register the fastest regional CAGR of 7.98% during 2026–2032. Treatment practices across China, India, Japan, and South Korea are advancing through improved hospital-based infection management, greater access to targeted antibiotics, and stronger antimicrobial stewardship programs. Increasing clinical attention to complicated skin infections and antibiotic-resistant pathogens is supporting the adoption of advanced antibacterial therapies.

 

Which FDA-Approved Antibiotics Are Expanding Treatment Options and Commercial Opportunities in the Acute Bacterial Skin and Skin Structure Infections Market?

Zevtera (Ceftobiprole Medocaril Sodium) – Advanced Cephalosporin Technology for Resistant Bacterial Infections

The FDA approved Zevtera on April 3, 2024, for adults with ABSSSI, among other indications. Developed by Basilea Pharmaceutica, Zevtera is an advanced-generation intravenous cephalosporin with activity against susceptible MRSA, MSSA, Streptococcus pyogenes, and Klebsiella pneumoniae. Its ability to target selected Gram-positive and Gram-negative pathogens provides an alternative for hospital-managed infections where broader antibacterial coverage is appropriate.

The FDA reviewed an ABSSSI clinical trial involving 679 patients, in which ceftobiprole achieved an early clinical response rate of 91.3%, compared with 88.1% for vancomycin plus aztreonam, meeting the trial's noninferiority criterion. These findings strengthen its clinical positioning in hospital antibiotic formularies and create opportunities for specialized cephalosporin adoption.

Baxdela (Delafloxacin) – Dual-Route Fluoroquinolone Therapy for Gram-Positive and Gram-Negative Pathogens

Baxdela is an FDA-approved anionic fluoroquinolone available in oral and intravenous formulations for adults with ABSSSI caused by designated susceptible bacteria, including MRSA. Its antibacterial spectrum covers selected Gram-positive and Gram-negative organisms, making it a treatment option when its susceptibility profile matches the suspected or identified pathogens.

Commercial differentiation comes from its oral and intravenous formulations, which allow physicians to transition eligible patients from hospital-administered therapy to outpatient oral treatment. This flexibility supports hospital discharge planning, outpatient prescription demand, and reduced dependence on prolonged intravenous antibiotic administration. Fluoroquinolone boxed warnings and patient-specific safety considerations remain important determinants of appropriate utilization.

Orbactiv (Oritavancin) – Single-Dose Lipoglycopeptide Technology for Outpatient Treatment

Orbactiv is an FDA-approved intravenous lipoglycopeptide for adult ABSSSI caused by susceptible Gram-positive bacteria, including MRSA, MSSA, selected streptococci, and vancomycin-susceptible Enterococcus faecalis. Its principal treatment advantage is a single 1,200 mg intravenous dose, compared with conventional antibiotic regimens requiring repeated administration.

The single-dose approach creates commercial opportunities within hospital outpatient departments, emergency departments, and infusion centers. It may reduce follow-up infusion requirements and allow selected clinically stable patients to complete antibiotic administration without prolonged hospitalization. Orbactiv therefore competes through treatment convenience, patient management efficiency, and potential reductions in selected healthcare resource costs.

Dalvance (Dalbavancin) – Extended-Half-Life Lipoglycopeptide Technology for Adult and Pediatric ABSSSI

Dalvance, associated with AbbVie, is a long-acting intravenous lipoglycopeptide approved for treating ABSSSI caused by susceptible Gram-positive bacteria, including MRSA. Its prolonged elimination half-life enables single-dose or two-dose treatment regimens in adults, providing an alternative to antibiotics that require daily administration. The drug also has an FDA-approved pediatric indication, extending its relevance to children with eligible bacterial skin infections.

The FDA's 2025 labeling documents pharmacokinetic evaluations involving 211 pediatric patients, supporting age-appropriate dosing across pediatric populations. Commercially, Dalvance offers opportunities in outpatient infusion services, hospital discharge programs, and selected cases where repeated intravenous treatment would otherwise require additional healthcare visits. Its value proposition centers on administration efficiency, antibacterial coverage, and treatment-site flexibility.

NUZYRA (Omadacycline) – Next-Generation Aminomethylcycline Technology with Oral and IV Flexibility

NUZYRA, developed by Paratek Pharmaceuticals, is an FDA-approved aminomethylcycline antibiotic available in oral and intravenous formulations for adult ABSSSI. It provides activity against designated susceptible Gram-positive and Gram-negative pathogens, including MRSA, and uses a modified tetracycline structure intended to retain activity against certain tetracycline-resistant organisms.

Its commercial significance comes from its dual-route treatment capability and once-daily maintenance dosing, enabling eligible patients to transition from hospital-based intravenous treatment to oral therapy. FDA prescribing information provides treatment regimens generally spanning 7–14 days, depending on the indication and clinical circumstances. NUZYRA therefore competes in the advanced tetracycline segment through pathogen coverage, outpatient suitability, and oral antibiotic accessibility.

Sivextro (Tedizolid Phosphate) – Short-Course Oxazolidinone Therapy for Gram-Positive Skin Infections

Sivextro, originally developed by Cubist Pharmaceuticals and subsequently incorporated into Merck's antibacterial portfolio, is an FDA-approved oxazolidinone antibiotic targeting susceptible Gram-positive ABSSSI pathogens, including MRSA. Its principal differentiation is a six-day adult treatment regimen with 200 mg once-daily administration, available through oral and intravenous formulations.

FDA labeling from 2026 also documents pediatric ABSSSI trials involving 166 patients, including adolescents and younger children, demonstrating the development of age-appropriate treatment regimens. In a pediatric adolescent trial, 91 patients received tedizolid for six days, compared with 29 receiving comparator therapy for ten days. These clinical characteristics support differentiated positioning in outpatient antibiotic therapy, particularly where oral treatment, dosing frequency, and treatment duration influence prescribing decisions.

Teflaro (Ceftaroline Fosamil) – MRSA-Active Cephalosporin Technology for Hospital-Based ABSSSI Treatment

Teflaro, a ceftaroline fosamil formulation historically associated with Allergan and later AbbVie, is an FDA-approved intravenous cephalosporin used to treat ABSSSI caused by designated susceptible bacteria, including MRSA and MSSA. Its distinguishing characteristic is its activity against MRSA, unlike many conventional cephalosporins, making it commercially relevant within specialized hospital antibacterial portfolios.

Ceftaroline's clinical positioning is particularly important for infections requiring intravenous treatment where MRSA coverage is indicated. The FDA established pediatric efficacy for ABSSSI in patients aged two months to under 18 years through supplemental labeling in 2016. Hospital formularies, susceptibility testing, and antimicrobial stewardship programs influence its adoption, while its broader treatment applications support procurement across acute-care settings.

 

Which Companies Are Leading Innovation and Competitive Development in the Acute Bacterial Skin and Skin Structure Infections Market?

Leading Company – AbbVie Inc.

Key ABSSSI Products: DALVANCE (dalbavancin) and TEFLARO (ceftaroline fosamil)

Core Technologies: Long-acting lipoglycopeptide antibiotics and MRSA-active cephalosporins.

AbbVie is a prominent competitor in the Acute Bacterial Skin and Skin Structure Infections Market, supported by its portfolio of FDA-approved antibiotics targeting serious Gram-positive bacterial infections, including MRSA. Its DALVANCE (dalbavancin) offers single-dose or two-dose intravenous treatment for eligible patients, while TEFLARO (ceftaroline fosamil) provides hospital-based treatment against susceptible bacterial pathogens, including MRSA. AbbVie lists both medicines in its pharmaceutical product portfolio.

Clinical evidence strengthens DALVANCE's commercial positioning. A randomized Phase III trial involving 698 ABSSSI patients demonstrated early clinical response rates of 81.4% with single-dose dalbavancin and 84.2% with the two-dose regimen, establishing noninferiority. At the later assessment, clinical success reached 84.5% and 85.1%, respectively. Its extended dosing interval supports outpatient infusion programs and can reduce the need for repeated antibiotic administration, creating opportunities in hospital discharge management and healthcare resource optimization.

Other Key Companies and Their Roles:

• Merck & Co., Inc.: Commercializes SIVEXTRO (tedizolid phosphate), an oxazolidinone antibiotic offering a six-day oral or intravenous treatment regimen for eligible ABSSSI patients.

• Pfizer Inc.: Supplies ZYVOX (linezolid), an oxazolidinone antibiotic targeting susceptible Gram-positive pathogens, including MRSA, in complicated skin and skin structure infections.

• GSK plc: Investigated gepotidacin, a novel bacterial topoisomerase inhibitor, in a Phase II ABSSSI study involving 122 adults, contributing to research on alternative antibacterial mechanisms.

• Basilea Pharmaceutica: Developed ZEVTERA (ceftobiprole), an advanced-generation cephalosporin targeting susceptible MRSA and other bacterial pathogens, commercially launched in the United States in May 2025 through Innoviva Specialty Therapeutics.

• Melinta Therapeutics: Developed BAXDELA (delafloxacin), an oral and intravenous fluoroquinolone offering coverage against selected Gram-positive and Gram-negative ABSSSI pathogens.

• Paratek Pharmaceuticals: Commercializes NUZYRA (omadacycline), a once-daily aminomethylcycline antibiotic available in oral and intravenous formulations for adult ABSSSI treatment.

• Melinta Therapeutics: Also has a role in long-acting antibiotic treatment through ORBACTIV (oritavancin), a single-dose intravenous lipoglycopeptide for susceptible Gram-positive ABSSSI pathogens.

 

Analyst Commentary: How Will Long-Acting Antibiotics and Oral Alternatives Shape Outpatient Treatment?

The Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market is witnessing a shift toward targeted antimicrobial therapies, particularly for MRSA and other resistant bacterial pathogens. Long-acting intravenous antibiotics, single-dose treatment regimens, and oral antibiotic alternatives are gaining importance in reducing hospital stays and supporting outpatient care. Increasing antimicrobial resistance, infection severity, and the need for effective treatment of cellulitis, major cutaneous abscesses, and wound infections are influencing antibiotic selection, treatment costs, and clinical adoption.

 

Acute Bacterial Skin and Skin Structure Infections Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 3.71 Billion
Revenue Forecast in 2032	USD 5.77 Billion
Overall Growth Rate	CAGR of 6.52% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million/Billion, CAGR (2026 – 2032)
Segmentation	By Infection Type, By Drug Class, By Route of Administration, By Pathogen Type, By Distribution Channel, By Geography
By Infection Type	Cellulitis/Erysipelas, Major Cutaneous Abscesses, Wound Infections
By Drug Class	Cephalosporins, Glycopeptides, Lipoglycopeptides, Oxazolidinones, Lipopeptides, Tetracyclines, Other Antibiotics
By Route of Administration	Intravenous (IV), Oral
By Pathogen Type	Methicillin-Resistant Staphylococcus aureus (MRSA), Methicillin-Susceptible Staphylococcus aureus (MSSA), Streptococcus Species, Other Bacterial Pathogens
By Distribution Channel	Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising burden of acute bacterial skin and skin structure infections, increasing prevalence of MRSA and other resistant bacterial pathogens, continued demand for effective intravenous antibiotics, growing adoption of oral step-down therapy, development of long-acting lipoglycopeptides, simplified single-dose and short-course treatment regimens, increasing outpatient infection management, and growing need for targeted antimicrobial therapies and antibiotic stewardship
Customization Option	Available upon request